Navigation Links
Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma
Date:2/10/2009

LONDON, Feb. 10 /PRNewswire/ -- Microdosing or Phase 0 clinical testing has been gaining acceptance and might become an imperative phase of the drug development process in the years to come. The emergence of niche capability providers in preclinical testing and technology dependence is also expected to result in numerous partnerships and alliances, fuelling growth opportunities in this sector.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

"There is every reason to believe that the solution for faster screening of candidates and increasing pressure on costs is gaining momentum in the right direction," notes Frost & Sullivan (http://www.pharma.frost.com) Senior Research Analyst V. Sriram. "The compelling advantages of microdosing present it as a potential remedy for big pharma's maladies regarding declining returns from investments in drug development."

Alliances between contract research organisations (CROs) in the U.S. and Europe have not historically been common. This is due to several factors including the industry's strong growth and relatively low technology demands for clinical testing. However, developments in microdosing should see a number of opportunities being investigated.

Consolidation within the CRO space has led to concerns over the quality of service and attention to detail. Companies must however ensure the quality of their services to maintain their bargaining power with the pharmaceutical companies.

"CROs face the challenge of competitively aligning their services to meet customer needs in order to overcome the threat of losing their stronghold and loyalty," comments Sriram.

Developing the technological know-how and expertise on niche capabilities will help CROs retain t
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Transport Pharmaceuticals Receives Coveted Frost & Sullivan Technology Innovation Award
2. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
3. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
4. Signalife Wins Second Frost & Sullivan Technology Award
5. AdvanDx Receives Frost & Sullivans Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
6. Modigene Announces Closing of $12 Million Financing by Members of The Frost Group
7. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
8. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
9. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. Frost & Sullivan Recognizes Kionixs Dominance in the MEMS Accelerometers Market Through Product Line Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four ... million and provides a good start to Q4.  The orders are ... and one in the Middle East . ... said Peter Bruijns , President & CEO. "Total bidding activity ... they have been for any complete year since the company has ...
(Date:10/20/2014)... N.J. (PRWEB) October 20, 2014 ... the Sidney Kimmel Cancer Center at Thomas Jefferson ... , Through the Strategic Alliance Partnership program, ... OncLive will collaborate to raise awareness of the ... treatment, and other projects. Clinicians and other health ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... The Asia-Pacific Speech Analytics market report ... with analysis and forecast of revenue. This market is ... $208 million by 2019, at a Compound Annual Growth ... Browse through the TOC of the Asia-Pacific Speech Analytics ... analysis provided. It also provides a glimpse of the ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... MedWaves, AveCure™ microwave coagulation-ablation (MWA) system uses ... (abnormal structures) safely, effectively, precisely and with repeatability. ... worldwide, including lesions in bone, kidney, liver, lung ... technology to treat lesions in other locations in ...
... LAUSANNE, Switzerland, and MALVERN, Pennsylvania, September 7, ... a global biopharmaceutical development specialist that focuses ... and Ascenta Therapeutics, Inc. (Ascenta), a privately-held, ... development of new medicines to treat cancer, ...
... portfolio of 16 Nanotechnology products and processes were ... organized to mark the fifty-second anniversary celebrations of ... portfolio, Director, Center of Excellence in Nanotechnology (CoEN) ... of products and processes demonstrates potential development of ...
Cached Biology Technology:MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices 2MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices 3Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T 2Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T 3AIT unveils portfolio of 16 nanotechnology products 2
(Date:10/14/2014)... the house fly genome for the first time, revealing ... insect that thrives in pathogen-rich dung piles and garbage ... journal Genome Biology , will increase understanding of ... quickly adapt to resist insecticides, which could lead to ... carry and transmit more than 100 human and animal ...
(Date:10/14/2014)... research team has discovered a new kind of stem cell ... that lines liver blood vessels, according to a study published ... existence of such a cell type contradicts current theory on ... may hold clues to origins of, and future treatment for, ... single cell into a complex being made up of more ...
(Date:10/14/2014)... 14, 2014 – Scientists from The Scripps Research Institute ... Institutes of Health (NIH) to lead an investigation of ... disease in Africa. The study aims to understand how ... die, while others survive the inflection. , "The ... mechanism of how Lassa fever virus causes disease and ...
Breaking Biology News(10 mins):House fly genome reveals expanded immune system 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... Chestnut due to an Asian bark fungus accidentally introduced to ... the tree was highly valued for its strong, workable lumber ... bears relied upon the chestnut for food. Ongoing efforts ... in part because they rely on genetic cross breeding ...
... Each year, millions of monarch butterflies ( Danaus plexippus ... colonize eastern North America, but just how these delicate ... breeding range in spring has largely remained a mystery. ... led by Prof. Ryan Norris, Department of Integrative Biology, ...
... -- Findings from a first-of-its-kind study by Indiana University ... or fantasies -- can lead to female orgasm. ... phenomenon, sometimes called "coregasm" because of its association with ... media for years, said Debby Herbenick, co-director of the ...
Cached Biology News:UC research tests new tool to guide reintroduction of the American chestnut 2UC research tests new tool to guide reintroduction of the American chestnut 3Study reveals how monarch butterflies recolonize northern breeding range 2Study: Exercise can lead to female orgasm, sexual pleasure 2Study: Exercise can lead to female orgasm, sexual pleasure 3
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
... PAGE Cleavable ICAT Reagent ... Protein ID and Quantitation ... Electrophoresis (PAGE), isotope-coded affinity ... technology to facilitate the ...
Supplemental reagent for annexin V assay....
Biology Products: